share_log

Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $72 Price Target

Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $72 Price Target

古根海姆重申買入ANI Pharmicals,維持72美元的目標股價
Benzinga ·  2023/10/19 13:39

Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $72 price target.

古根海姆分析師Vamil Divan重申ANI製藥(納斯達克:ANIP)買入,並維持72美元的目標價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論